Skip to main content
. 2008 Sep 1;26(25):4116–4123. doi: 10.1200/JCO.2008.16.7460

Table 2.

Characteristics of Patients With Lung Cancer and Survival Rates

Predictor No. of Patients % No. of Patients Dead Survival Time (months)
Hazard Ratio 95% CI P2)
Median 95% CI
Sex
    Male 1,047 66 1,001 10.5 9.9 to 11.1
    Female 530 34 490 12.1 11.0 to 13.4 0.84 0.75 to 0.94 .0024
Race
    White 1,331 84 1,252 11.1 10.6 to 11.8
    Black 168 11 164 10.2 8.6 to 12.2 1.17 0.99 to 1.39
    Hispanic 40 3 40 9.2 6.8 to 13.3 1.13 0.82 to 1.56
    Other 38 2 35 9.4 7.4 to 14.6 1.09 0.78 to 1.54 .2800
Age, years*
    < 50 180 11 171 10.0 8.5 to 11.0
    50-59 425 27 401 11.1 10.3 to 12.6 0.89 0.74 to 1.07
    60-69 619 39 585 11.8 11.1 to 12.8 0.83 0.70 to 0.99
    70+ 353 22 334 9.5 8.4 to 10.9 0.93 0.77 to 1.12 .1567
Marital status
    Single 101 6 100 9.5 8.1 to 10.7
    Married 1,047 66 977 11.2 10.4 to 12.2 0.81 0.66 to 1.00
    Separated 39 2 38 12.1 8.0 to 14.0 0.94 0.64 to 1.37
    Divorced 225 14 220 10.6 9.7 to 11.6 0.95 0.75 to 1.21
    Widowed 165 10 156 11.7 9.5 to 13.5 0.81 0.62 to 1.04 .1060
PS
    0 609 39 556 14.7 13.6 to 16.1
    1 820 52 789 9.8 9.0 to 10.4 1.47 1.31 to 1.64
    2 148 9 146 6.1 3.9 to 7.5 2.52 2.06 to 3.08 < .0001
Chest pain
    No 1,073 68 1,006 11.8 11.0 to 12.7
    Yes 504 32 485 9.5 8.4 to 10.5 1.27 1.13 to 1.42 < .0001
Dyspnea
    No 802 51 740 12.3 11.3 to 13.3
    Yes 775 49 751 10.0 9.4 to 10.7 1.26 1.14 to 1.40 < .0001
Bone pain
    No 1,325 84 1,244 11.6 10.9 to 12.3
    Yes 252 16 247 7.6 6.7 to 9.2 1.28 1.11 to 1.48 .0006
CNS symptoms
    No 1,513 96 1,431 11.0 10.5 to 11.7
    Yes 64 4 60 8.5 6.0 to 10.9 1.24 0.95 to 1.62 .1123
Duration of symptoms, months
    < 3 1,050 67 993 10.9 10.3 to 11.6
    3-6 361 23 342 10.7 9.0 to 11.8 1.00 0.88 to 1.13
    > 6 166 11 156 11.8 10.3 to 13.9 0.93 0.78 to 1.10 .6938
Weight loss, %
    None to < 5 1,169 74 1,095 12.6 11.7 to 13.5
    ≥ 5 408 26 396 7.4 6.5 to 7.8 1.55 1.37 to 1.75 < .0001
Liver metastases
    No 1,353 86 1,271 11.8 11.1 to 12.7
    Yes 224 14 220 6.4 5.8 to 7.4 1.49 1.27 to 1.75 < .0001
Adrenal metastases
    No 1,418 90 1,335 11.5 11.0 to 12.2
    Yes 159 10 156 6.4 5.7 to 7.6 1.29 1.08 to 1.55 .0055
Bone metastases
    No 1,285 81 1,202 12.2 11.4 to 12.9
    Yes 292 19 289 7.4 6.2 to 8.0 1.34 1.16 to 1.54 < .0001
Brain
    No 1,555 99 1,470 11.0 10.5 to 11.6
    Yes 22 1 21 6.5 3.2 to 13.6 1.24 0.78 to 1.98 .3644
WBC ≥ 8.7 × 103
    No 768 49 718 12.2 11.4 to 13.6
    Yes 809 51 773 9.9 9.0 to 10.6 1.20 1.08 to 1.33 .0005
Hemoglobin ≥ 14.6 g/dL
    No 1,271 81 1,206 10.4 9.8 to 11.0
    Yes 306 19 285 13.4 12.2 to 14.6 0.80 0.70 to 0.92 .0014
Platelets ≥ 400,000
    No 1,138 72 1,072 12.2 11.5 to 13.3
    Yes 437 28 417 8.5 7.8 to 9.3 1.34 1.19 to 1.51 < .0001
Alkaline phosphatase ≥ 100 U/mL
    No 853 54 798 12.6 11.6 to 13.6
    Yes 721 46 690 9.1 8.5 to 10.2 1.24 1.11 to 1.38 < .0001
Education
    Grades 1-8 206 13 196 11.3 9.7 to 13.9
    Grades 9-11 284 18 273 11.0 9.8 to 12.9 1.04 0.86 to 1.26
    High school graduate 524 33 496 10.5 9.5 to 11.4 1.06 0.90 to 1.26
    Some college 355 23 333 11.3 10.3 to 12.6 0.94 0.78 to 1.12
    College degree 208 13 193 11.1 10.0 to 13.1 1.00 0.81 to 1.23 .5141

Abbreviation: PS, performance status.

*

Age at enrollment onto clinical trial.